Becton Dickinson and Co (NYSE:BDX) – Analysts at KeyCorp issued their Q1 2020 earnings per share estimates for Becton Dickinson and in a note issued to investors on Tuesday, November 12th. KeyCorp analyst M. Mishan anticipates that the medical instruments supplier will post earnings of $2.60 per share for the quarter. KeyCorp currently has a “Overweight” rating and a $256.00 price target on the stock. KeyCorp also issued estimates for Becton Dickinson and’s Q2 2020 earnings at $3.01 EPS, Q3 2020 earnings at $3.25 EPS, Q4 2020 earnings at $3.66 EPS, FY2020 earnings at $12.57 EPS and FY2021 earnings at $14.19 EPS.
A number of other equities research analysts have also weighed in on the stock. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies lowered their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, Wells Fargo & Co lowered their target price on shares of Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $265.55.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The company had revenue of $4.58 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter in the prior year, the business posted $2.93 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year.
In other news, EVP Alexandre Conroy sold 9,829 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total transaction of $2,506,984.74. Following the completion of the sale, the executive vice president now owns 16,535 shares in the company, valued at approximately $4,217,417.10. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the sale, the chief executive officer now owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,174 shares of company stock valued at $8,354,013. Company insiders own 0.12% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Eagle Asset Management Inc. purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth approximately $2,062,000. GAM Holding AG boosted its holdings in Becton Dickinson and by 56.4% in the 2nd quarter. GAM Holding AG now owns 48,870 shares of the medical instruments supplier’s stock worth $12,316,000 after buying an additional 17,622 shares during the period. CIBC Asset Management Inc boosted its holdings in Becton Dickinson and by 0.5% in the 2nd quarter. CIBC Asset Management Inc now owns 53,480 shares of the medical instruments supplier’s stock worth $13,477,000 after buying an additional 247 shares during the period. Black Diamond Financial LLC bought a new position in Becton Dickinson and in the 2nd quarter worth approximately $562,000. Finally, Findlay Park Partners LLP boosted its holdings in Becton Dickinson and by 8.3% in the 2nd quarter. Findlay Park Partners LLP now owns 2,220,000 shares of the medical instruments supplier’s stock worth $559,462,000 after buying an additional 170,000 shares during the period. Institutional investors own 84.52% of the company’s stock.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: How liquidity affects the bid-ask spread
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.